drugset / Trial / NCT04098744
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Phase 2
Recruiting
78 enrolled
Frantz Viral Therapeutics, LLC
Amarex Clinical Research · collabFlorida Gynecologic Oncology · collabHarris Health System (L.B.J. Hospital) · collabM.D. Anderson Cancer Center · collabThe Cleveland Clinic · collabUniversity of Michigan · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Timeline
- Start
- 2020-09-09
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 200 mg | Other |